Fulgent Genetics, Inc. reiterated earnings guidance for the year 2024. For the full year 2024, Fulgent continues to expect Core Revenue of approximately $280 million and GAAP loss of approximately $2.25 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.39 USD | +1.18% | -3.26% | -26.01% |
May. 03 | Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024 | |
May. 03 | Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.01% | 633M | |
-23.07% | 8.1B | |
+68.36% | 4.26B | |
+1.88% | 2.57B | |
-8.06% | 2.49B | |
-41.95% | 2.39B | |
-11.99% | 1.77B | |
-21.18% | 1.53B | |
+17.44% | 1.2B | |
-43.89% | 1.18B |
- Stock Market
- Equities
- FLGT Stock
- News Fulgent Genetics, Inc.
- Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024